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Abstract: Cancer is one of the leading causes of death worldwide, with a mortality rate of more than
9 million deaths reported in 2018. Conventional anti-cancer therapy can greatly improve survival
however treatment resistance is still a major problem especially in metastatic disease. Targeted
anti-cancer therapy is increasingly used with conventional therapy to improve patients’ outcomes in
advanced and metastatic tumors. However, due to the complexity of cancer biology and metastasis,
it is urgent to develop new agents and evaluate the anti-cancer efficacy of available treatments.
Many phytochemicals from medicinal plants have been reported to possess anti-cancer properties.
One such compound is known as oridonin, a bioactive component of Rabdosia rubescens. Several
studies have demonstrated that oridonin inhibits angiogenesis in various types of cancer, including
breast, pancreatic, lung, colon and skin cancer. Oridonin’s anti-cancer effects are mediated through
the modulation of several signaling pathways which include upregulation of oncogenes and pro-
angiogenic growth factors. Furthermore, oridonin also inhibits cell migration, invasion and metastasis
via suppressing epithelial-to-mesenchymal transition and blocking downstream signaling targets
in the cancer metastasis process. This review summarizes the recent applications of oridonin as an
anti-angiogenic and anti-metastatic drug both in vitro and in vivo, and its potential mechanisms
of action.
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1. Introduction
Cancer metastasis is considered the main cause of cancer mortality [1]. Even though
metastatic cancer can be treated, this disease is generally considered incurable with a low
survival rate [1,2]. Tumor metastasis is a dynamic multistep event that involves changes in
various biochemical, genetic and epigenetic factors in the primary tumor that contributes
to the invasion–metastasis cascade. This series of metastatic cascade begins with the
invasion of the primary tumor cells into the surrounding tissues which is governed by
the epithelial-to-mesenchymal transition (EMT) followed by the tumor cells entering the
circulatory system and extravasating through the vascular walls into the parenchyma of
distant tissues to form secondary cancers [3]. Tumor vascularization and angiogenesis
are required for the dissemination and establishment of cancer metastasis [4]. According
to Weinberg and Hanahan, inducing angiogenesis and the ability to invade surrounding
tissues and metastasize are hallmarks of tumor malignancy [4].
New agents that present anti-cancer effects are largely tested for their ability to cause
tumor shrinkage which focuses mainly on inhibiting cell division and proliferation. How-
ever, in advanced stages, cancer cells begin to invade the extracellular matrix (ECM), induce
the EMT process, and create secondary tumors. The current cancer treatment strategies
such as chemotherapy are often associated with adverse side effects and greatly affects
the quality of life. Moreover, treatment resistance is also often observed when cancer is
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presented at an advanced stage [5]. It is therefore important to vigorously identify new
agents with low susceptibility to drug resistance and to explicitly block key molecules or
their downstream signaling targets in the cancer metastasis process.
Natural products derived from Chinese medicinal plants have recently attracted a
growing interest in the treatment of cancer, especially those with low side effects such as
shikonin, berberine, and curcumin [6]. In China, Rabdosia rubescens is used as an alternative
medicine to treat sore throat, gingivitis, and rheumatoid arthritis [7,8]. Oridonin (C20H28O6)
(Figure 1) is an active diterpenoid component from Rabdosia rubescens first identified in
1966 by Furida and colleagues [9]. Oridonin possesses many therapeutic potentials such as
neuroprotective [10], anti-inflammatory [11] and antibacterial [12] effects. In recent years,
the anti-cancer properties of oridonin were studied in a wide range of tumors including
breast [13], colon [14], pancreatic [15], lung [16], gastric [17], prostate [18] and skin [19]
cancer. This review discusses the different molecular pathways involved in angiogenesis,
cell invasion, and metastasis that can be targeted by oridonin.
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2. The Process of Angiogenesis as a Target of Oridonin
Tumor angiogenesis is a highly regulated process through which new blood vessels
form in the tumor environment to upply oxygen and support tumor growth [20]. In
this process, extensive interplays between endothelial cells, angiogenic growth factors,
and ECM is required [20,21]. In tumor angiogenesis, various pro-angiogenic signals
such as vascular endothelial growth factor (VEGF), pidermal growth factor (EGF), and
transforming growth factor (TGF) are released to induce the formation of blood vessels and
to support tumor proliferation [20,22]. Such a process is also referred to as the ‘angiogenic
witch’ and can occur at different a es of tumor prog ession as a result of genetic or
microenvironmental changes [23]. During the switch, tumors in dormancy re-enter the cell
cycle and become actively growing malignant cells [23,24]. One of the angiogenic models
includes new vessels sprouting from pre-existing ones in the tumor microenvironment [25].
In this process, endothelial cells e erge towards an angiogenic stimulus, and endothelial
cells involved are classified into tip and stalk cells [25]. The tip cells are responsible for
ECM degradation while the stalk cells facilitate vascular lumen formation [26,27]. During
sprouting angiogenesis, VEGF and Notch signaling are activated to guide the vascular
patterning by directing the tip cell migration and stalk cell proliferation. VEGF can induce
jagged ligands which then increases Notch expression in cancer endothelial cells to promote
Notch-dependent angiogenesis [28]. VEGF also activates other signaling cascades such as
phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated protein kinase. After the
establishment of new blood vessels, platelet-derived growth factor β (PDGF) is secreted to
assist the maturation process of blood vessels [25]. In addition to sprouting angiogenesis,
cancer cells use vascular mimicry to acquire blood supply [29]. Highly invasive tumors can
differentiate into endothelial cells and induced tube-like structures. This allows tumors to
have a secondary circulatory system that is not dependent on angiogenesis [29].
Based on the understanding of the diverse pathways involved in angiogenesis, strate-
gies to inhibit the formation of new blood vessels in tumors can be applied at different
stages such as targeting the proangiogenic factors or disrupt the active dividing endothelial
cells. Over the years, many anti-angiogenic inhibitors have been developed such as beva-
cizumab [30] and sunitinib which target VEGF pathways [31]. VEGF is one of the most
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extensively studied angiogenic factors and a key mediator in tumor angiogenesis. The
VEGF family has at least seven isoforms (i.e., VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E,
placental growth factor, and VEGF-F) that bind to the tyrosine kinase receptor known as
vascular endothelial growth factor receptor (VEGFR) [32]. High expression of VEGF has
been reported in many cancers such as breast [33], prostate [34], and ovarian [35] cancer.
Targeting angiogenesis has so far shown limited success, which may be attributed
to the heterogeneity of blood vessels in the tumor environment and tumor hypoxia [20].
The newly formed blood vessel in tumor is usually abnormal in structure with immature
and leaky blood vessels. Unlike normal blood vessels, the tumor vessels are narrower
in diameter, have diverse vessel density, and high permeability [36]. Moreover, tumor
blood vessels are not efficient in delivering oxygen and removal of waste products which
can lead to an aggressive tumor microenvironment [20]. As a result of the abnormality
of tumor blood vessels, the efficacy of anti-cancer treatment may be decreased due to
the inaccessibility of the drug to the tumor area and increased drug resistance [25]. The
development of new anti-angiogenic agents with high efficacy and fewer side effects is
needed to overcome resistance to the existing agents and improve cancer therapy.
In recent years, oridonin has been shown to be a promising anti-angiogenic agent.
Dong and coworkers reported that oridonin inhibits angiogenesis by blocking VEGF-
induced micro-vessels sprouting. In human umbilical vein endothelial cells (HUVEC) cells,
oridonin treatment reduced more than 90% tubular formation [37]. In another study, Jiang
and colleagues reported that VEGF-induced migration was reduced following oridonin
treatment. The tubular formation was also decreased by 70% in the oridonin treated group
when compared to the control group. Also, oridonin treatment has resulted in irregular and
disorganized tube formation and the depolymerization of F-actin [38]. Vascular assay in
zebrafish embryos showed that oridonin reduced the diameter of the complete intersegment
vessels when compared to the control group [39]. Taken together, these suggest that
oridonin may interfere with capillary network formation and actin organization.
The key targets of oridonin to suppress angiogenesis include VEGF, Notch, and PI3K
signaling pathways. Oridonin has been shown to inhibit the expression of the VEGF family
such as VEGF-A, VEGFR-2, and VEGFR-3 [39–41]. In endothelial cells, when VEGF binds to
its receptor, the VEGF/PI3K signaling pathway is activated to induce vessel formation [42].
Oridonin also inhibited the VEGF-induced Notch activation by reducing the expression
of key ligand and downstream genes including Jagged-1 and -2, Notch 1, Hes-1, HESR-1,
and DII-1 [37]. The inhibition of VEGF expression by oridonin ultimately leads to the
suppression of angiogenesis due to the inactivation of its downstream targets.
The combination treatment of chemotherapy agents with anti-angiogenic inhibitors
has been shown to improve treatment efficacy in ovarian cancer. For example, the adminis-
tration of bevacizumab with selected chemotherapy agents such as pegylated liposomal
doxorubicin and paclitaxel improved progression-free survival in platinum-resistant ovar-
ian cancer [43]. Li and colleagues explored the potential of an anti-angiogenesis effect of
oridonin in combination with doxorubicin [44]. Treatment with doxorubicin alone did
not inhibit cell migration and invasion of HUVECS cells. However, oridonin treatment
as a single agent resulted in reduced VEGF-induced endothelial cell migration and tube
formation. Interestingly, the combination of both compounds synergistically impedes
cell migration and invasion of HUVECS cells. Based on the molecular docking study,
a combination of the two compounds showed a high affinity towards the ATP-binding
domain of VEGFR-2 kinase which suggests that the interaction may inhibit the activation
of VEGFR-2 [44]. Figure 2 summarizes the effect of oridonin on angiogenesis.
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3. Oridonin in EMT
EMT is a complex biological process in which epithelial transitions into a mesenchy-
al p enotype and it is one of th important events in driving tumor progression and
metastasis [45]. In EMT, epithelial cells lose their epithelial characteristics and gain motile
mesenchymal properties such as loss of cell-cell adhesion, augmented motility, and inva-
siveness [46]. The shift from one stat to another is controlled by a range of growth factors
and signaling pathways [47]. The strong integration between these growth factors such as
TGF-β forms a robust network promoting the growth of cancer cells and that makes EMT a
possible target for cancer metastases. There are various ways to target the EMT process in
cancer which include (i) blocking the activation signal of EMT markers such as E-cadherin,
N-cadherin vimentin, fibronectin, matrix metalloproteinases (MMPs), and TGF-β [48],
(ii) reversed the EMT process, and (iii) suppressing the growth EMT-like cells. E-cadherin
and N-cadherin share a similar structure and are involved in cell-cell adhesion [46]. On the
other hand, vimentin and fibronectin play a role in maintaining cell shape and cell adhesion,
respectively [49,50]. The reduced expression of E-cadherin along with the concomitant
increased expression of specific mesenchymal markers such as zinc finger E-box binding
homeobox 1 (ZEB1), N-cadherin, and vimentin are considered hallmarks of EMT [46,51].
Growing evidence showed that oridonin exhibits anti-metastatic effects by altering the
EMT pathway. To date, the effects of oridonin on the EMT pathways have been reported
in many cancers such as pancreatic, breast, melanoma, and lung cancer. Previous studies
suggest that oridonin increased E-cadherin expression while decreased the expression of
ZEB1, N-cadherin, fibronectin, vimentin, snail, and slug [52–54]. The MMPs play a pivotal
role in cancer cell invasiveness and metastasis by facilitating ECM degradation [55]. As an
invasion promoter, MMPs can facilitate EMT through invasion and metastasis behaviors
(i.e., regulation of actin cytoskeleton, increase motility, and proliferation) [56]. Various
studies demonstrated that oridonin could inhibit the expression of MMP-2 and MMP-9 in
various cancers such as breast [13], acute myeloid leukemia [57] bone [58], and ovarian [59]
cancer. Oridonin also decreased MMP-12 expression which is an important mediator to
degrade ECM in lung cancer [60]. The effects of oridonin on EMT makers and regulators
are summarized in Table 1.
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Table 1. Effects of EMT markers modulated by oridonin.
EMT Marker Cancer Type Cell Line Concentration and Treatment Time Effect References
ZEB1 Pancreatic
BxPC-3 87.8–95 µM (24 h) Downregulation of ZEB1
protein expression
[52,53]
PANC-1 55.8 µM–95 µM (24 h)
E-cadherin
Pancreatic
BxPC-3 95 µM (24 h) Enhances of E-cadherin
protein expression
[53]
PANC-1 95 µM (24 h)
SW1990 15 µM (24 h) Enhances of E-cadherinprotein expression [61]
Breast
MDA-MB-231
4–16 µM (24 h) Upregulation of E-cadherin





0.8–2 µM (24 h) Upregulation of E-cadherin
mRNA and protein expression
[54]
143B
Lung H1688 5–10 µM (24 h) Upregulation of E-cadherinmRNA and protein expression [16]
N-cadherin
Pancreatic
BxPC-3 87.8–95 µM (24 h) Downregulation of N-cadherin
protein expression
[52,53]
PANC-1 55.8 µM–95 µM (24 h)
Breast
MDA-MB-231
4–16 µM (24 h)
Downregulation of N-cadherin





0.8–2 µM (24 h) Downregulation N-cadherin




BxPC-3 87.8 µM (24 h) Downregulation of fibronectin
protein expression
[52]




4–16 µM (24 h)
Downregulation of vimentin
mRNA and protein expression
[40]
4T1
Pancreatic SW1990 15 µM (24 h) Downregulation of vimentinmRNA levels [61]
Bone
MG-63
0.8–2 µM (24 h) Downregulation of vimentin
mRNA and protein expression
[54]
143B
Lung H1688 5–10 µM (24 h) Downregulation of vimentinmRNA and protein expression [16]
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SW1990 15 µM (24 h) Decreases snail mRNA levels [61]
BxPC-3










Lung H1688 5–10 µM (24 h) Downregulation of snail mRNAand protein expression [16]
Skin
A375






SW1990 15 µM (24 h) Decreases slug mRNA levels [61]
BxPC-3











Lung H1688 5–10 µM (24 h) Downregulation of slug mRNAand protein expression [16]
MMP-2
Breast MDA-MB-231 1–5 µM (24 h) Downregulation of MMP-2protein expression [13]
AML MV4-11/DDP 10–80 µM (48 h) Downregulation of MMP-2protein expression [59]
Bone U2OS 15–60 µM (48 h) Downregulation of MMP-2protein expression [58]
Ovarian A2780/DDP 10–80 µM (48 h) Downregulation of MMP-2protein expression [57]
MMP-3 Bone U2OS 15–60 µM (48 h) Downregulation of MMP-3protein expression [58]
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Table 1. Cont.
EMT Marker Cancer Type Cell Line Concentration and Treatment Time Effect References
MMP-9
Breast MDA-MB-231 1–5 µM (24 h) Downregulation of MMP-9protein expression [13]
AML MV4-11/DDP 10–80 µM (48 h) Downregulation of MMP-9protein expression [59]
Bone U2OS 15–60 µM (48 h) Downregulation of MMP-9protein expression [58]
Ovarian A2780/DDP 10–80 µM (48 h) Downregulation of MMP-9protein expression [57]
MMP-12 Lung H1975 10–20 µM (24 h) Downregulation of MMP-12protein expression [60]
Abbreviations: epithelial-to-mesenchymal transition (EMT); zinc finger E-box binding homeobox 1 (ZEB1), matrix metalloproteinases (MMP); acute myeloid leukemia (AML); messenger RNA (mRNA).
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4. Cancer Invasion and Metastasis
The invasion-metastatic pathway is a multi-step process that starts with the invasion of
the cancer cells into the surrounding tissues (Figure 3). In this process, the release of MMPs,
hyaluronidase, and metalloproteinase (ADAM) are required to assist ECM degradation
and remodeling [63]. Following ECM degradation, tumor cells then migrate into the
blood and lymphatic vessels crossing the endothelial cell barrier and this step is known
as intravasation. Cancer cells escape into the circulation either as single circulating tumor
cells (CTC) or as clustered CTC. To promote cancer cells transmigration into the circulatory
system and protect them from external insults, various growth factors and cytokines are
released including tumor necrosis factor 1-α (TNF1-α), TGF-β, VEGF, and EGF [3]. The
release of EGF and TGF-β enhances the intravasation process by allowing the cancer cells
to cross blood vessels barriers [64]. To establish a secondary tumor at a distant tissue
site, cancer cells need to extravasate from the vascular system. The releases of integrins,
insulin-like growth factor-1 (IGF-1), VEGF, MMP, PDGF, and help to facilitate cancer
cell extravasation [3] (Figure 3). Integrins support the anchorage-independent survival
of CTC while VEGF and IGF1 induce vascular permeability to allow them to penetrate
endothelial cells and migrate into tissue parenchyma [65]. Metastatic colonization begins
once cancer cells survive the stressful processes of intravasation and extravasation. In this
stage, cancer cells can either proliferate continuously or enter dormancy [66]. The tumor
microenvironment at the metastatic site plays a key role in determining whether cancer
cells can survive. Factors such as favorable conditions in ECM, effective vascular system,
ability to escape immune system surveillance, and resistance to anoikis will determine
whether cancer cells enter dormancy or proliferate into macrometastases [66].
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metastatic cascades. These include targeting the early steps in the metastatic processes,
prevent tumor dissemination into the circulatory system, and killing dormant cancer
cells [65]. Over the years, various inhibitors targeting key molecules in cancer metastasis
have been developed such as MMP, VEGF, and endothelial growth factor receptor (EGFR)
inhibitors [65,67]. However, many of these agents failed to show efficacy and safety in
clinical trials [68,69]. Identification of an agent that can inhibit a target integral to multiple
stages of metastasis can significantly enhance metastasis inhibition and increase patient
survival. Oridonin has been reported to exhibit an anti-metastatic effect in cancer. Ori-
donin inhibits cancer cells invasion and metastasis through targeting various transcription
factors and their signaling pathways such as TGF-β1 [70], EGFR [60], mammalian target of
rapamycin (mTOR) [71], long non-coding RNAs (lncRNAs) [53] as well as increasing the
activity of tumor suppressor genes (i.e., p53 and protein phosphatase 2A (PP2A)) [72]. The
effects of oridonin on these targets are discussed below.
4.1. Oridonin Inhibits TGF-β/Smad Pathway
In human cancers, dysregulation of TGF-β is common in many human cancers such as
prostate and bone cancer [73,74]. In the early stage of cancer development, TGF-β acts as a
tumor suppressor, but as cancer progresses TGF-β enhances cancer cell invasiveness and
increases metastases [75]. Smad is activated by phosphorylation via TGF-β1, translocates
to the nucleus where it forms a complex that works as a transcription factor and triggers a
cascade of gene expression involved in cell migration such as integrins and MMPs [76,77].
In osteosarcoma, 24 h treatment with low concentrations of oridonin (0.5–2 µM) decreased
the migration and invasion capabilities of 143B and MG-63 bone cancer cells by significantly
inhibiting the phosphorylation of TGF-β and preventing the Smad dimer from translocating
into the nucleus [54]. Bu and coworkers also demonstrated that oridonin blocks the
activation of the TGF-β1/Smad signaling pathway in colon cancer. In this study, pre-
treatment with 8 µg/mL of oridonin for 48 h downregulated the phosphorylation of TGF-
β1 downstream effectors like Smad proteins (Smad2, Smad3, and Smad4) and subsequently
deactivated plasminogen activator inhibitor type 1 (PAI-1), a molecule regulated by Smad
pathway [70].
Oridonin was shown to inhibit the cellular migration and invasion and decrease
the number of cells adhesiveness to fibronectin in B16-F10 (mouse) and A375 melanoma
cancer (human) cells via downregulation of TGF-β1 expression and inhibition of the
PI3K/Akt/GSK-3β signaling pathway [78]. In a recent study, treatment with oridonin
(4–16 µM) for 24 h inhibited regulatory T cell (Treg) differentiation in 4T1 murine breast
cancer cells via downregulation of the protein levels of TGF-β receptor, Smad2, and Smad3.
In vivo study also demonstrated that oridonin at doses of 2.5, 5 and 10 mg/kg reduced Treg
phosphorylation thereby suppressing breast cancer growth and progression [79]. Such data
suggest that oridonin exhibits an anti-metastatic effect by inhibits TGF-β/Smad pathway.
4.2. Oridonin Blocks the Activation of EGF/EGFR/ERK Signaling Pathways
High expression of EGFR was observed in many tumors such as in lung, breast, and
ovarian cancer [80,81]. The aberration in EGFR expression and downstream signaling
influenced tumor progression and maintenance of the malignant phenotype [82]. Phos-
phorylation of EGFR activates the extracellular-signal-regulated kinase (ERK) pathway
that is involved in various pathological processes including angiogenesis, migration, and
invasion. In lung cancer, treatment with oridonin (0–10 µM) for 24 h suppressed cell
migration, invasion, and adhesion of H1975 human non-small cell lung cancer (NSCLC)
cell line through suppression of phosphorylation of EGFR and its downstream signaling
pathway via ERK [60]. Protein phosphatase 2A (PP2A) is a tumor suppressor gene that in-
activates the ERK pathway [83]. Xiao and colleagues demonstrated that oridonin (0–10 µM)
increased PP2A activity and inactivated the ERK/Akt pathway which resulted in inhibition
of cell migration and invasion of H1975 NSCLC cells after 24 h treatment. The inhibition of
the ERK/Akt pathway also promoted apoptosis in these cells [60]. Previous studies have
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reported that in transformed cells and cancer cell lines, inhibition of PP2A promotes cell
motility [84,85]. The activation of the ERK pathway is also mediated by focal adhesion
kinase (FAK) [86]. The activation of FAK can lead to increased motility of cancer cells.
Wang and colleagues showed that treatment with oridonin (1.25–5 µM) for 24 h inhibits
MDA-MB-231 breast cancer cell motility and migration activities via suppression of FAK
and integrin β1 expressions [13]. In H1688 NSCLC cell line, oridonin at a concentration of
10 µM markedly inhibited cell migration via downregulating the expression of metallopro-
teinases and phosphorylated FAK (p-FAK) [61]. The inhibition of EGF/EGFR signaling
pathway by oridonin results in the suppression of ERK and FAK leading to a decrease in
cell motility, migration, and invasion capacities of cancer cells.
4.3. Oridonin Inhibits the Phosphorylation of mTOR Signaling Pathway
Growing evidence supports the role of mTOR is in cancer cell invasion and metastasis
especially by regulating the organization of actin cytoskeleton [87,88]. The anti-invasive
and anti-metastatic effects of oridonin via inhibiting the mTOR pathways have been studied
in ovarian cancer. The treatment with oridonin at 2.5 to 10 µM for 24 h decreased cell
migration and invasion of SKOV3 ovarian cancer cells by blocking the phosphorylation
of the mTOR signaling pathway [71,89]. The inhibition of mTOR is also accompanied by
the upregulation of forkhead box P3 (FOXP3) following oridonin treatment [89]. FOXP3
plays a role in regulating the function of regulatory T-cell [90]. Moreover, FOXP3 was
also reported to play role in cancer metastasis [91]. Previous studies also showed that the
inhibition of mTOR by oridonin induced cell apoptosis [92,93]. Such findings suggest that
the inhibition of mTOR signaling pathways and the involvement of FOXP3 are essential
for the anti-tumorous effect of oridonin.
4.4. Oridonin Downregulates the lncRNA AFAP1-AS1 Expression
The long non-coding RNAs (lncRNAs) are involved in various biological processes
including cell differentiation, proliferation, growth, and apoptosis [94]. RNA actin filament-
associated protein 1 antisense RNA 1 (AFAP1-AS1) is a recently identified cancer-associated
lncRNA originating from the antisense DNA strand of the AFAP1 coding gene locus. The
aberrant expression of lncRNAs is frequently reported in cancer [95]. In pancreatic can-
cer, overexpression of lncRNA AFAP1-AS1 is associated with low survival and disease
progression [96]. As a result, lncRNA AFAP1-AS1 has become a possible target in the
treatment of pancreatic cancer. A recent study has shown that treatment with oridonin
(95 µM) and/or knockdown of lncRNAs AFAP1-AS1 for 24 h inhibited cell invasion capac-
ity of PANC-1 and BxPC-3 pancreatic cancer cell lines as assessed by transwell migration
assay. In lncRNA AFAP1-AS1 knockdown cells, oridonin treatment resulted in fewer
cells penetrating through the membranes in transwell assays compared to siAFAP1-AS1
alone. The author suggested that oridonin maintained AFAP1-AS1 inhibition which fur-
ther decreased the metastasis activity of PANC-1 and BxPC-3 cells [53]. This indicates
that oridonin increases its anti-metastatic effect against pancreatic cancer by continuously
inhibiting AFAP1-AS1.
4.5. Oridonin Increases the Expression of p53
Any mutations or loss in the p53 tumor suppressor gene can result in uncontrolled cell
division, avoidance of apoptosis, and changes in cell migration and polarity [97]. Studies
have shown that loss of p53 function is associated with an increase in cell motility and
hence facilitates cancer development and metastases [97,98]. The p53 level and activity are
mainly mediated by ubiquitin E3 ligase Mdm2, which binds directly to p53 and facilitates
p53 ubiquitination and proteasomal degradation [99]. Mdm2 is known as the principal
negative regulator of p53 [99]. Treatment with oridonin (10–80 µM) for 24 h was shown
to suppress the migration activity of SNU-16 gastric cancer cells via apoptosis, increase
the expression of p53, and downregulate the expression of Mdm2. The inhibitory effect
of oridonin was reversed in a stable knockdown of p53 by siRNA in SNU-16 cells validat-
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ing the above observation [72]. A previous study reported that p53 mutations occur at
a late stage in cancer progression pathway in 56% of gastric carcinoma cases [100]. The
mutational spectrum of p53 in gastric cancer is wide however, the most common sites
occur at codon 175, 213, 245, 248, 273, and 282 [101]. An increase in p53 level and activ-
ity following oridonin treatment (20–40 µM) was also observed in other cancer such as
neuroblastoma [102] and esophageal [103] cancer. Taken together, these data propose that
oridonin exert its anti-cancer activity by enhancing p53 protein expression in cancer cells
and promotes apoptosis.
5. Oridonin in Hypoxia
Hypoxia is the main feature of solid tumors and it arises as a result of uncontrolled
proliferation of cancer cells which limit the availability of oxygen supply and, often as-
sociated with poor overall survival [104,105]. The unorganized vascular networks at the
tumor site make a significant contribution to a reduced level of oxygen in the solid tu-
mor [104]. In metastatic cancer, hypoxia serves as one of the main drivers for cancer to
develop a more aggressive and resistant phenotype as well as enhanced survival in a
nutrient-deprived environment [106,107]. This is because hypoxia increases the expression
of many angiogenic inflammatory markers and growth factors in cancer cells particularly
VEGF-A [108]. Besides, hypoxia may induce EMT by promoting the transcription of EMT
markers such as Snail, ZEB1, and TWIST [107]. The activation of hypoxia-induced EMT
markers promotes cancer cell motility, migration, and invasion, resulting in tumor progres-
sion and metastases [109]. Hypoxia-inducible factor 1 (HIF-1α) is a major transcriptional
regulator in hypoxia which can directly or indirectly regulate EMT markers [109]. For
instance, HIF-1α may activate N-cadherin and vimentin to mediate EMT by promoting
the loss of cell-cell adhesion which subsequently results in more migratory and invasive
cancer cells. HIF-1α has been considered a therapeutic target for the treatment of cancer
metastasis by inhibiting HIF-1 and its downstream molecules using bioreductive drugs
and gene therapy [110]. Bioreductive drugs are inactive agents that undergo biotransfor-
mation to generate highly reactive electrophiles through enzymatic reduction catalyzed
by endogenous oxidoreductases. The activation of such agents occurs in hypoxic regions
where oxygen levels are low [111]. Examples of these agents include tirapazamine, mit-
omycin C and E09. These agents, however, showed limited success in clinical trials due
to toxicity and rapid clearance [112,113]. Therefore, it is important to identify new agents
that can target hypoxia without inducing severe toxicity. Oridonin has been shown to
inhibit hypoxia-induced migration and EMT via targeting HIF-1α. In human gallbladder
cancer cells (GBC-SD), treatment with 5 µM of oridonin for 24 h significantly inhibited EMT
and reversed hypoxia-induced migration via downregulation of HIF-1α/MMP-9 signaling
pathways. Similarly, in tumor xenograft tissue, treatment with 5 µM of oridonin suppressed
the protein expression of HIF-1α and MMP-9 [114]. In MDA-MB-231 and 4T1 breast cancer
cells, treatment with increasing concentration of oridonin (0–16 µM) for 24 h inhibited
angiogenesis and cell migration via downregulation of HIF-1α protein expression [40].
Taken together, these findings suggest that, through downregulation of HIF-1α protein
expression, oridonin is able to suppress cell migration, angiogenesis and EMT.
6. Conclusions and Future Perspectives
Disturbance of metastases processes carries a great amount of clinical significance
for patients with or at risk of developing metastatic cancer. Herbal medicines have long
been an essential source for the discovery and development of new drugs against human
diseases. The use of natural products in the treatment of cancer has gained the attention
of the research community due to low cost and few side effects. In this review, we have
summarized many potential therapeutic advantages of oridonin particularly in targeting
angiogenesis and metastasis. The anti-angiogenic effect of oridonin is observed in its ability
to target VEGF and suppress the formation of blood vessels. Moreover, when combined
with other chemotherapy drugs such as doxorubicin, the effectiveness of treatment is im-
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proved. The ability of oridonin to interrupt several metastasis pathways holds preclinical
promise for its development as a potential anti-metastatic agent in clinical settings. Ori-
donin has been shown to inhibit cell migration and invasion by targeting several metastatic
signaling pathways. However, as tumor metastasis is a complex disease, more studies on
other metastatic pathways should be considered. Over the years, researchers also have
developed novel oridonin analogs such as HAO472 [115], CYD-6-17 [116], 1-O- and 14-O-
derivative compounds [117]. The development of these novel analogs is aimed to improve
oridonin’s water solubility and therapeutic efficacy. Many of these agents, however, have
not been tested for their anti-angiogenic and anti-metastatic effects. Additional research is
warranted to explore the potential therapeutic benefits of oridonin and its derivatives in
the management of metastatic cancer especially in animal models and clinical trials.
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VEGF vascular endothelial growth factor
EGF epidermal growth factor
TGF transforming growth factor
VEGFR vascular endothelial growth factor receptor
MMP matrix metalloproteinases
ZEB1 zinc finger E-box binding homeobox 1
ADAM metalloproteinase
CTC circulating tumor cells
TNF1-α tumor necrosis factor 1-α
PDGF platelet-derived growth factor
IGF-1 insulin-like growth factor-1
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mTOR mammalian target of rapamycin
NSCLC human non-small cell lung cancer
ERK extracellular-signal-regulated kinase
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